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Thioredoxin interacting protein (TXNIP) is an attractive candidate gene




 is the strongest glucose-
responsive gene in pancreatic B-cells, TXNIP deficiency in a mouse model is




 is located in the 1q21-1q23
chromosomal Type 2 diabetes mellitus (DM) locus. We set out to investigate
whether metabolic effects of TXNIP that were previously reported in a murine








 UTR single nucleotide poly-


























 230). Metabolic data were used to determine the effect of this SNP on




The frequency of the TXNIP variation did not differ between groups,
but within the group of diabetic subjects, carriers of the TXNIP-T variant had














 136) and a 5.5-mmHg














 212) than homozygous carriers
of the common C-allele, whereas in non-diabetic subjects fasting glucose was














 478) in carriers of the T-allele. Moreover,
a significant interaction between plasma glucose concentrations and TXNIP


















This is the first report to implicate TXNIP in a human disorder of
energy metabolism, Type 2 diabetes. The effect of TXNIP on triglycerides is
influenced by plasma glucose concentrations, suggesting that the biological
relevance of TXNIP variations may be particularly relevant in recurrent episodes
of hyperglycaemia.
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apo, apolipoprotein; BMI, body mass index; DBP, diastolic
blood pressure; FCHL, familial combined hyperlipidaemia; GCNF, germ cell
nuclear factor; HOMA, homeostasis model assessment; IGT, impaired glucose
tolerance; NGT, normal glucose tolerance; PCR, polymerase chain reaction; SBP,
systolic blood pressure; SNP, single nucleotide polymorphism; T2DM, Type 2
diabetes mellitus; TRX, thioredoxin; TXNIP, thioredoxin interacting protein;
USF-1, upstream stimulatory factor 1; VEGF, vascular endothelial growth factor
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In several human populations, the 1q21-1q23 chromosomal
area has been implicated in Type 2 diabetes mellitus (T2DM)
[1] as well as in familial combined hyperlipidaemia (FCHL)
[2]. In general, both T2DM and FCHL are believed to be
determined by a disease-predisposing genetic background in
concert with environmental risk factors such as obesity [3].
Moreover, subjects with T2DM and FCHL express common
metabolic abnormalities, i.e. high plasma concentrations of
fatty acids and/or triglycerides and insulin resistance. HcB19
mice are phenotypically characterized by inherited hyper-
lipidaemia, especially hypertriglyceridaemia, and hepatic
steatosis [4], two conditions that are common in both T2DM
and FCHL [5,6]. Therefore, data obtained with this recently
described mouse model of inherited hyperlipidaemia may be
useful for gene discovery in these related human diseases.
The gene defect in these hyperlipidaemic HcB19 mice is a
truncation in thioredoxin interacting protein (TXNIP) [7],
which is located in a chromosomal region that is syntenic with




 was initially proposed as
a candidate gene for FCHL [7], but was later excluded for
this disease in different populations [8–10]. More recently,




) has been identified
as the most likely causal gene for hyperlipidaemia in FCHL in
this chromosomal locus [8]. Although the 1q21-23 locus is
also implicated in T2DM and hypertriglyceridaemia is present
in up to 50% of White T2DM patients [11], recent evidence




 may not be a very relevant gene
in diabetes [12,13]. For these and additional reasons (discussed




 gene is involved in
the development of hypertriglyceridaemia in diabetes.
Several indirect lines of evidence support the hypothesis that
variations in TXNIP activity may affect an individual’s sus-
ceptibility to development of diabetes. First, TXNIP regulates
cellular thioredoxin (TRX) activity [14] and targeted expression
of TRX in the pancreas protects B-cells against autoimmune-









 is the strongest glucose-





Lastly, increased insulin concentrations have been reported in
TXNIP-deficient HcB19 mice [17], although this was not the
case in the original HcB19 report [4]. These functional data
on the roles of TXNIP and thioredoxin, combined with the
chromosomal localization of TXNIP on 1q21-23 and the
hypertriglyceridaemic effect of the truncation in HcB19 mice,





may affect susceptibility to T2DM or to hypertriglyceridaemia
in T2DM.
It was the objective of the present study to analyse associa-








 gene and several aspects of human diabetes in a popu-
lation enriched in risk factors for T2DM. First, we established
whether TXNIP variations could influence the risk of Type 2
diabetes in humans. Next, the effects of the TXNIP variant on
plasma lipid variables were determined in healthy subjects and
diabetes patients. Finally, the effects of TXNIP variation on other










 gene is involved in the develop-
ment of hypertriglyceridaemia in diabetes was investigated in
the CODAM (COhortstudy on Diabetes and Atherosclerosis
Maastricht; 574 subjects) population, extended with 270
subjects collected by the National Institute of Public Health
(RIVM) according to exactly the same criteria [18,19]. Assign-

























 230) status was
done on the basis of an oral glucose tolerance test according
to the 1999 World Health Organization criteria [20]. In the
majority of the NGT, IGT and T2DM subjects, the following
plasma parameters were determined using standard laboratory
techniques [18]: apolipoprotein (apo) A and apoB, total and
high-density lipoprotein cholesterol, triglycerides, glucose,
insulin, free fatty acids, C-reactive protein. Urinary albumin
concentrations and anthropomorphic markers such as waist
circumference, height, weight, waist–hip ratio, body mass index
(BMI) and blood pressure were also determined [21]. ApoA and
apoB were determined in serum by auto analyser (Hitachi 912)
using a Roche kit (Roche Diagnostics, Almere, the Netherlands).
Homeostasis model assessment (HOMA-IR) was used to assess
insulin resistance [22].
Participants provided informed consent and the studies were
approved by local ethics committees. General characteristics
of the groups with different glucose tolerance states are presented
in Table 1.
 




 is a very small gene, spanning a genomic region of




 UTR sequence of human TXNIP
mRNA consists of 1307 nucleotides followed by a poly A tail
(http://www.ensembl.org; v40, August 2006). The single nucle-





402 base-pairs downstream of the TXNIP coding region (http:
//ncbi.nlm.nih.gov/SNP/). The C-allele (major allele) contains a
restriction enzyme site for SnaB1 that is absent in the T-allele
(minor allele). This particular SNP was chosen since it was a
confirmed SNP with an acceptable reported average allele
frequency of 25.5% T and 74.5% C (http://www.ncbi.nlm.
nih.gov). DNA was prepared from peripheral blood mononu-
clear cells (QiaAmp DNA blood mini kit; Qiagen, Hilden,
Germany). Polymerase chain reaction (PCR) amplification was


















 (backward primer). The amplification
reactions contained 12.5 pmol of each primer, 0.75 U of Taq













C was used and the reaction was
cycled for 35 repeats. Digestion of the PCR products with 5 U
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in 889- and 184-bp fragments for the C-allele and 1073 bp
for the T-allele. Restriction fragments were separated on a
1.5% agarose gel and visualized with ethidium bromide. Each
time the assay was performed, DNA from a known CC and a
known CT individual was included as a positive control (TT




Presence of Gaussian distribution was analysed for all variables.
Variables not having a Gaussian distribution were log trans-

















variables are presented as median (interquartile range) and dif-





No correction for multiple testing was applied since the choice
of the variables was largely based on the physiological data
available in the TXNIP-deficient mouse model. Using our cur-
rent knowledge of the allele frequency of the T-allele (see Re-
sults), the number of subjects in our analyses provided us with




 gene when the difference between carriers and non-
carriers was 0.3 mmol/l for triglycerides, 0.4 mmol/l for glucose
or 5 mmHg for diastolic blood pressure (DBP) (Quanto version
1.1 [23]). For these calculations we used data from a control
population representative of Dutch subjects of similar age to
our currently used populations, i.e. the spouse control subjects
from our study on FCHL [21]. Thirty-two subjects had not
stopped their lipid-lowering medication prior to the blood
collection and were excluded from the analyses which included
lipid parameters. Differences in metabolic parameters were
adjusted for age, gender, BMI and site of data sampling, as
indicated using linear regression analysis. In linear regression




 –3 and < 3, and
normal distribution of the residuals was verified. All analyses




TXNIP polymorphism and prevalence of diabetes
 
The allele distributions of the TXNIP C/T polymorphism
(rs#2711) were consistent with Hardy–Weinberg equilibrium
in all groups. We have analysed this polymorphism in more
than 1800 subjects (control, diabetic and hyperlipidaemic
subjects from different populations, all White). The mean
frequency of carriers of the minor T-allele was 7.8% (range
5.3–13.9%) in different control and patient populations,
frequencies which are consistent with data currently reported
for populations of White descent (http://www.ensembl.org).
In the population reported here, the frequency of T-allele














 0.4) between groups with


























 20 of 215). No homozygous carriers of the
TXNIP minor allele (TT) were identified.
 





Data on TXNIP genotype and blood pressure were available for
812 subjects (of the 837 included in the study; see also Tables 1
Table 1 General characteristics of the study population
Glucose tolerance status
Non-diabetic subjects Diabetic subjects ANOVA/Kruskal–Wallis 
NGT IGT T2DM P-value
Age (years)* 58 ± 7 58 ± 7 60 ± 7  0.002
BMI (kg/m2)* 27.5 ± 3.8 29.3 ± 4.2 30.5 ± 4.3 < 0.001
Percent male* 59 61 68 NS
Fasting glucose (mmol/ l)* 5.3 ± 0.5 5.9 ± 0.6 7.8 ± 1.8
Insulin (µU/ml)* 7.2 (5.8–9.9) 9.3 (6.4–13.9) 12.0 (8.4–18.2)
HOMA-IR* 1.7 (1.3–2.3) 2.3 (1.6–3.7) 4.2 (2.7–6.3)
ApoB (g/ml)* 1.1 ± 0.2 1.2 ± 0.2 1.1 ± 0.2 NS
Cholesterol (mmol/ l) 5.3 ± 0.9 5.6 ± 1.0 5.4 ± 1.2 < 0.001
Triglycerides (mmol/ l)* 1.2 (0.9–1.7) 1.6 (1.1–2.2) 1.8 (1.2–2.4) < 0.001
Free fatty acids (mmol/ l)* 0.48 ± 0.16 0.55 ± 0.19 0.60 ± 0.21 < 0.001
HDL-cholesterol (mmol/ l)* 1.3 ± 0.3 1.2 ± 0.3 1.1 ± 0.3 < 0.001
ApoA (g/ml)* 1.5 ± 0.2 1.5 ± 0.2 1.4 ± 0.2  0.002
Diastolic BP (mmHg)* 79.1 ± 9.0 82.4 ± 10.3 84.6 ± 9.3 < 0.001
Systolic BP (mmHg)* 128.0 ± 17.0 133.0 ± 18.4 139.8 ± 18.1 < 0.001
*Age, body mass index (BMI), gender and blood pressure and high-density lipoprotein (HDL)-cholesterol were available for 379 normal glucose 
tolerance (NGT), 228 impaired glucose tolerance (IGT) and 230 Type 2 diabetes mellitus (T2DM) subjects; fasting glucose levels were available 
for 327 NGT, 157 IGT and 170 T2DM subjects; fasting apolipoprotein (apo) B, triglycerides, free fatty acids, apoA, insulin and homeostasis 
model assessment of insulin resistance (HOMA-IR) were available for 284 NGT, 128 IGT and 145 T2DM subjects.
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and 2). DBP was 5.5 mmHg higher in T2DM subjects with the
TXNIP-CT genotype than in CC individuals [P = 0.013; 95%
confidence interval (CI) 1.2, 9.9, adjusted for age, gender
and sampling site], but there was no effect in NGT and IGT
subjects. Additional adjustment for BMI did not substantially
change these data (P = 0.02; 95% CI 0.8, 9.5 mmHg). Systolic
blood pressure (SBP) did not differ significantly between
diabetic carriers of the TXNIP-T allele (143.5 ± 20.9 mmHg)
and homozygous diabetic carriers of the major C-allele
(139.1 ± 17.8 mmHg; Student’s t-test P = 0.21, adjusted
for age, gender, BMI and sampling site). Urinary albumin con-
centrations were also higher in diabetic carriers of the TXNIP-T
allele [16.1 mg/l (10.2–24.9), median (interquartile range); n = 7]
than in diabetic TXNIP-CC subjects [6.0 mg/l (3.15–13.05);
n = 101, P = 0.019].
Fasting triglycerides
Data on TXNIP genotype and fasting triglycerides were
available for a total of 546 subjects (see Tables 1 and 2).
Plasma triglyceride concentrations were 1.6-fold higher in
diabetic carriers of the TXNIP minor T-allele than in dia-
betic CC individuals (95% CI 1.1, 2.3-fold; P = 0.013,
adjusted for age, gender and sampling site). Additional
adjustment for BMI did not substantially change these data
(P = 0.015; 95% CI 1.1, 2.3). There were no obvious effects
of the TXNIP genotype in triglyceride levels in the NGT and
IGT subjects.
Indicators of glucose metabolism and insulin resistance
Data on TXNIP genotype and fasting glucose were available
for 638 subjects (see Tables 1 and 2). Fasting glucose was
0.26 mmol/l lower in NGT subjects with the TXNIP-CT
genotype than in CC individuals (P = 0.009; 95% CI −0.45,
−0.063, adjusted for age, gender and sampling site). Fasting
glucose levels were also lower in IGT carriers of the TXNIP-
CT genotype, but this did not reach statistical significance
(0.25 mmol/l; P = 0.12, adjusted for age, gender and sampling
site). Additional adjustment for BMI decreased P-values slightly
(P = 0.008 and P = 0.07 for NGT and IGT, respectively).
Analysis of all non-diabetic subjects combined (i.e. all NGT
and IGT subjects), strengthened this relation, resulting in a
0.26 mmol/l lower fasting glucose in non-diabetic carriers of
the T-allele compared with non-diabetic TXNIP-CC individuals
[P = 0.002, 95% CI −0.42, −0.09; adjusted for age, gender,
BMI, glucose-tolerance-status (NGT of IGT) and sampling site]
This effect of the TXNIP polymorphism on glucose was absent
in the T2DM subjects (P > 0.8). There were no significant
effects of the TXNIP polymorphism on HOMA-IR or plasma
insulin concentrations in any of the groups.
Interaction of the TXNIP genotype with parameters of glucose 
homeostasis
It was recently reported that TXNIP is a highly glucose-
responsive gene in the pancreatic β-cell [16]. Moreover, Hui
et al. [17] have suggested that the hyperlipidaemia in the
TXNIP-deficient HcB19 mouse model may, at least in part,
be secondary to hyperinsulinaemia. We investigated, using
linear regression analysis, whether plasma glucose concentra-
tions per se or, alternatively, presence of insulin resistance or
hyperinsulinaemia, interacted with the TXNIP gene poly-
morphism in the effect on plasma triglyceride levels. There was
a significant interaction between fasting plasma glucose
concentrations and the TXNIP genotype on plasma trigly-
ceride concentration [P = 0.012 for the interaction term
(TXNIP × glucose) adjusted for age, gender and BMI; Table 3,
n = 544]. No interaction was observed between plasma insulin
Table 2 Characteristics of carriers and non-carriers of the TXNIP-T allele in NGT, IGT and Type 2 diabetes subjects
Non- diabetic subjects Diabetic subjects
NGT IGT T2DM 
TXNIP-CC TXNIP-CT TXNIP-CC TXNIP-CT TXNIP-CC TXNIP-CT
Cholesterol (mmol/ l)† 5.3 ± 0.9 5.3 ± 1.0 5.5 ± 1.0 5.7 ± 0.9 5.4 ± 1.2 5.6 ± 0.8
Triglycerides (mmol/ l)† 1.2 (0.9–1.7) 1.3 (1.1–1.5) 1.6 (1.1–2.0) 1.8 (1.4–2.5) 1.6 (1.2–2.3) 2.0 (1.6–5.0)*
Fasting glucose (mmol/ l)† 5.3 ± 0.5 5.0 ± 0.5** 5.9 ± 0.7 5.6 ± 0.5 7.8 ± 1.8 7.9 ± 2.2
HOMA-IR† 1.7 (1.4–2.3) 1.7 (1.9–4.8) 2.3 (1.6–3.6) 2.5 (1.9–4.8) 4.3 (2.7–6.4) 3.3 (2.3–5.3)
Diastolic BP (mmHg)† 79.2 ± 9.1 78.6 ± 7.8 82.1 ± 10.7 84.5 ± 10.8 84.0 ± 9.5 89.1 ± 8.6**
Systolic BP (mmHg)† 128.2 ± 17.0 127.5 ± 17.7 132.4 ± 18.4 139.1 ± 19.2 139.1 ± 17.8 143.5 ± 20.9
The data presented are unadjusted mean ± SD or median (interquartile range) values.
†Data on blood pressure were available in 350/28 normal glucose tolerance (NGT), 196/23 impaired glucose tolerance (IGT) and 195/20 
Type 2 diabetes mellitus (T2DM) (TXNIP-CC/TXNIP-CT). Fasting glucose was available in 302/22 NGT, 138/16 IGT and 148/12 T2DM 
(TXNIP-CC/TXNIP-CT). Fasting triglycerides, cholesterol and homeostasis model assessment of insulin resistance (HOMA-IR) were available 
in 268/16 NGT, 111/15 IGT and 127/9 T2DM (TXNIP-CC/TXNIP-CT). Statistical differences between TXNIP-CC and TXNIP-CT within 
groups with different glucose tolerance status (NGT, IGT, T2DM): *P < 0.05, **P < 0.025 (unadjusted P-values); Student’s t-test/Mann–
Whitney U-test). P-values adjusted for age, gender, sampling site and body mass index (if applicable) are provided in the text.
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concentration or HOMA-IR and the TXNIP polymorphism
on plasma triglyceride concentrations [interaction (TXNIP ×
insulin), P = 0.9, interaction (TXNIP × HOMA-IR), P = 0.3,
adjusted for age, gender, BMI, disease status, TXNIP genotype
and insulin/HOMA].
Discussion
Genetic and metabolic data in the current literature prompted
us to investigate whether the TXNIP gene might play a role in
human metabolism, and more specifically in the development
of human diabetes and/or the hyperlipidaemia associated with
diabetes. TXNIP is a highly glucose-responsive gene [16] and
a recent report by Minn et al. [24] has shown that glucose
directly stimulates TXNIP expression via a carbohydrate response
element (CHOre) in the promoter of this gene. The overall fre-
quency of the TXNIP variation did not differ between diabetic
and non-diabetic subjects, implying that this polymorphism
did not affect the risk of T2DM in these subjects. However,
genetic variations in the TXNIP gene did significantly affect
several parameters associated with diabetes.
The TXNIP polymorphism influences triglyceride meta-
bolism. Plasma triglyceride concentrations were elevated in
diabetic carriers of the TXNIP-T allele, but not in non-diabetic
T carriers. This was confirmed in additional analyses: trigly-
ceride concentrations were influenced by a significant interaction
between plasma glucose concentration and the TXNIP poly-
morphism. This latter aspect is of particular interest because
of the previously mentioned regulation of TXNIP expression
by glucose [16] and suggests that the biological relevance of
TXNIP variations may be particularly important when glycaemic
control is inadequate. High plasma glucose concentrations in
diabetes reflect insufficient amounts of plasma insulin, which
is most likely associated with a relative glucose deficit in the
cells and might subsequently compromise TXNIP expression.
This effect might be more pronounced, i.e. may have greater
metabolic consequences, in carriers of the T-allele. Indeed,
hyperglycaemia in diabetes is often associated with hyper-
triglyceridaemia [25,26]. Interestingly, interaction between
TXNIP and plasma glucose concentration on plasma triglyceride
could also explain, at least in part, the absence of effect of the
TXNIP polymorphisms on hypertriglyceridaemia in FCHL
[8–10] that was confirmed in our own FCHL patients (data
not shown), because FCHL patients generally remain normo-
glycaemic, despite insulin resistance and hyperinsulinaemia.
Our data suggest that the potential of an individual to utilize
glucose for energy homeostasis, which is altered in diabetes,
may interfere with a metabolic effect of the TXNIP polymor-
phism. The TXNIP-T allele is associated with lower fasting
glucose levels in the non-diabetic state, but with hypertriglyc-
eridaemia in diabetic subjects. This is in line with previously
reported mouse data. It has been suggested that TXNIP may
act as a regulator or switch in fuel utilization, possibly via
changes in the cellular redox status [17,27]. Absence of TXNIP
in mice induced, among others, an altered hepatic response to
nutrient signals [17] and disturbances in the fasting–refeeding
transition [27] and, of interest, both these studies reported
reduced fasting glucose concentrations in TXNIP-deficient mice.
Our present data are based on the results of one SNP in the
3′ UTR of the TXNIP gene, and not all metabolic variables
were available for all subjects. In addition, we used a relatively
small study population, although the power calculation sug-
gested that we did have acceptable power to detect the differ-
ences reported here. A larger study population would possibly
also have allowed us to detect more subtle differences. Despite
these limitations, it is noteworthy that two of the three vari-
ables found to be affected by this TXNIP polymorphism in our
human study population, i.e. triglycerides and glucose, match
those that were earlier reported in the murine model
[4,7,17,27,28]. The phenotypic changes associated with the
minor TXNIP T-allele in our human subjects were analogous
to those reported in the TXNIP-deficient HcB19 mouse model.
This suggests that the most likely effect of the TXNIP T-allele
is a decreased amount of (functional) TXNIP protein, possibly
Table 3 Linear regression model describing the interaction between the effects of fasting glucose concentration and the TXNIP polymorphism on 
plasma triglyceride concentration
All subjects*
B Std B P-value R2
Overall 
P-value
Constant −0.149  0.10 0.139 < 0.001
Age (years) −0.002 −0.063  0.12
Gender (male = 0, female = 1) −0.020 −0.047  0.24
Body mass index (kg/m2) 0.008 0.165 < 0.001
Fasting glucose (mmol/ l)† 0.033 0.241 < 0.001
TXNIP genotype (CC = 0; CT or TT = 1)† 0.072 0.091  0.025
Interaction (TXNIP genotype × fasting glucose)† 0.049 0.102  0.012
*Normal glucose tolerance, n = 283; impaired glucose tolerance, n = 126, Type 2 diabetes mellitus, n = 135.
†Centred variables were used to reduce multicollinearity.
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accompanied by higher cellular thioredoxin activity. A possi-
ble consequence of a polymorphism in the 3′ UTR region of a
gene is a change in RNA stability or translation efficiency. The
position of rs#7211 is in the proximal one-third of the 3′ UTR,
almost 1000 bases away from the poly A tail. Moreover, the
region surrounding the SNP is not particularly AU-rich. It is
therefore unlikely to influence the stability through influencing
the poly A tail. Analysis the human and rat 3′ UTR sequence
with rVista 2.0/Transfac [29] revealed a conserved binding site
covering the SNP for germ cell nuclear factor (GCNF). How-
ever, based on the currently known functions of GCNF, which
are mainly related to embryonic development and germ cell
maturation (as reviewed in [30]), this factor does not appear to
be a very plausible candidate for regulation of TXNIP. There-
fore, the exact implications of the presence of this particular
SNP remain to be established.
The TXNIP-T allele was also associated with higher levels of
DBP in the diabetic subjects. Blood pressure had not been
previously addressed in the murine model and we had no clear
prior expectations of effects of this polymorphism on blood
pressure. The association between higher DBP and the pres-
ence of the minor TXNIP T-allele was independent of plasma
triglyceride concentrations and BMI. As discussed above, the
TXNIP-T allele is most likely associated with decreased TXNIP
activity and, consequently, with higher cellular thioredoxin
activity. An interesting aspect in this regard is that thioredoxin
can induce the expression of vascular endothelial growth
factor (VEGF) [31]. This reveals a possible pathway via which
the TXNIP-T allele may be associated with higher VEGF
expression. Increased VEGF concentrations, in turn, have been
reported to induce diabetic nephropathy [32,33], which is
reflected by, for example, microalbuminuria. It is well known
that microalbuminuria is associated with increased blood
pressure [34,35]. Thus, the presence of the TXNIP-T allele, if
associated with lower cellular levels of TXNIP and increased
thioredoxin activity, higher VEGF expression and increased
microalbuminuria, could potentially explain, at least in part,
the increase in DBP observed in the diabetic carriers of the
TXNIP-T allele. Although this mechanism is highly specula-
tive, the higher DBP in the diabetic carriers of the TXNIP-T
allele we report in our current study was indeed accompanied
by significantly increased urinary albumin concentrations, sug-
gesting that renal dysfunction was commoner in these subjects.
In conclusion, we have established that interaction between
a genetic variation in the TXNIP gene and fasting plasma
glucose affects plasma triglyceride concentrations in human sub-
jects. This suggests that variations in this gene may be particularly
relevant in human metabolic disorders with recurrent episodes
of poor glycaemic control. Indeed, the 3′ UTR polymorphism in
TXNIP was specifically associated with hypertriglyceridaemia
in human Type 2 diabetic subjects. In addition, an effect on
DBP was seen which was independent of plasma triglyceride
concentrations. The association of the TXNIP polymorphism
with hypertriglyceridaemia and increased blood pressure may
potentially contribute to cardiovascular risk in T2DM.
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